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Abstract
Cancer pain significantly affects the quality of cancer patients, and current treatments for this pain
are limited. C-Jun N-terminal kinase (JNK) has been implicated in tumor growth and neuropathic
pain sensitization. We investigated the role of JNK in cancer pain and tumor growth in a skin cancer
pain model. Injection of luciferase-transfected B16-Fluc melanoma cells into a hindpaw of mouse
induced robust tumor growth, as indicated by increase in paw volume and fluorescence intensity.
Pain hypersensitivity in this model developed rapidly (<5 days) and reached a peak in 2 weeks, and
was characterized by mechanical allodynia and heat hyperalgesia. Tumor growth was associated with
JNK activation in tumor mass, dorsal root ganglion (DRG), and spinal cord and a peripheral
neuropathy, such as loss of nerve fibers in the hindpaw skin and induction of ATF-3 expression in
DRG neurons. Repeated systemic injections of D-JNKI-1 (6 mg/kg, i.p.), a selective and cell
permeable peptide inhibitor of JNK, produced an accumulative inhibition of mechanical allodynia
and heat hyperalgesia. A bolus spinal injection of D-JNKI-1 also inhibited mechanical allodynia.
Further, JNK inhibition suppressed tumor growth in vivo and melanoma cell proliferation in vitro.
In contrast, repeated injections of morphine (5 mg/kg), a commonly used analgesic for terminal
cancer, produced analgesic tolerance after 1 day and did not inhibit tumor growth. Our data reveal a
marked peripheral neuropathy in this skin cancer model and important roles of the JNK pathway in
cancer pain development and tumor growth. JNK inhibitors such as D-JNKI-1 may be used to treat
cancer pain.
Introduction
Cancer pain significantly affects the diagnosis, quality of life and survival of patients with
cancer (Mantyh, 2006). The mechanisms of cancer pain are incompletely understood. Tumor
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growth may produce inflammation in tumor bearing tissues, which will release inflammatory
mediators to stimulate nociceptors. Tumor growth may also compress the peripheral nerves in
tumor bearing tissues, inducing nerve injury. Therefore, cancer pain is likely to share
mechanisms of inflammatory pain or/and neuropathic pain, although this pain may have
distinct mechanisms (Honore, et al., 2000; Mantyh, 2006). Whether inflammatory or
neuropathic pain mechanisms dominate during tumor growth may depend on the interactions
between tumor cells and surrounding tissues and nerves (Cain, et al., 2001; Wacnik, et al.,
2001). In recent years, several laboratories have developed cancer pain models by inoculation
of tumor cells into a hindpaw of mouse (Constantin, et al., 2008; Sasamura, et al., 2002), which
has mixed nociceptive/neuropathic pain. Since the measurement of tumor growth and cancer
pain is relatively easy in hindpaws of rats and mice and spinal cord innervations of hindpaw
are well documented, skin cancer pain model provides a useful tool to investigate mechanisms
of cancer pain.
Malignant melanoma is a major cause of death from skin cancer and its incidence has increased
significantly in the United States (Jemal, et al., 2001). Although pain is not a major symptom
of melanoma in clinic, 7% patients still experienced pain (Negin, et al., 2003). Also, metastatic
melanoma is associated with pain (in some case neuropathic pain) and more than 50% of the
patients require palliative care and morphine treatment (Leach, et al., 2008; Lehembre, et al.,
2006). In addition, animals inoculated with melanoma cells into the plantar of the hindpaw
show marked pain hypersensitivity (Andoh, et al., 2008; Mao-Ying, et al., 2006; Xia, et al.,
2006). Therefore we inoculated luciferase-transfected B16-Fluc melanoma cells into a hindpaw
of mouse, which allows us to perform bioluminescent imaging of melanoma growth in live
mice (Craft, et al., 2005) and reliably measure pain sensitivity and tumor growth in the hindpaw.
C-Jun N-terminal kinase (JNK) is a member of mitogen-activated protein kinases (MAPK) and
responsible for the activation of transcription factor c-Jun. JNK plays an important role in cell
mitosis, differentiation and stress (Ji, et al., 2007; Nateri, et al., 2005). C-Jun is critical for
tumor progression (Eferl, et al., 2003) and was regarded as a potential target of anticancer
therapy (Gurzov, et al., 2008). Interestingly, c-Jun is over-expressed in a large fraction of
human melanoma samples (Lopez-Bergami, et al., 2007). The small molecule inhibitor of JNK,
SP600125 inhibits cancer cell proliferation in cultures. Further, systemic administration of
SP600125 results in the inhibition of DU145 human prostate carcinoma xenografts and murine
Lewis lung carcinoma (Ennis, et al., 2005).
Recently, we found that the JNK pathway is activated in the spinal cord after nerve injury and
spinal injection of JNK inhibitors can attenuate nerve injury-induced neuropathic pain
(Zhuang, et al., 2006). In particular, a cell-permeable peptide inhibitor of JNK, D-JNKI-1 is
very selective and inhibits JNK activity by blocking JNK interaction with its substrate (Borsello
and Bonny, 2004). In a neuropathic pain model, D-JNKI-1 is 50 times more potent than
SP600125 in attenuating mechanical allodynia after intrathecal injection (Zhuang, et al.,
2006). Now we report that systemic administration of D-JNKI-1 can suppress both cancer pain
and tumor growth in a murine model of melanoma.
Methods
Animals
Experiments were done on adult male C57BL6 mice (8 weeks old, Charles River, MA),
weighing 22–24 g. All mice have free access to food and water with a 12/12 light cycle. The
Harvard Medical School Animal Care Committee approved all animal procedures in this study.
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Cell Culture and Tumor Inoculation
Murine melanoma cell line, B16-Fluc, was kindly provided by Dr. Noah Craft of University
of California, Los Angeles. The B16 murine melanoma cells (ATCC, Rockville, Maryland)
were transduced with a lentiviral construct containing the Fluc gene and the GFP gene,
separated by an encephalomyocarditis virus internal ribosomal entry site, and driven by an
internal CMV promoter (Craft, et al., 2005).
B16-Fluc cells were grown in Dulbecco’s modified Eagle medium containing 4,500 mg/l
glucose, 100 mg/l penicillin, 100 mg/l streptomycin, and supplemented with 10% fetal bovine
serum in 5% CO2/95% air at 37°C. Cells were subcultured or collected following enzymatic
digestion using trypsin solution. The melanoma cells (6 × 105 cells/30 μl) suspended in
phosphate buffered saline (PBS) were subcutaneously injected into the plantar region of mice
left hindpaw.
Behavioral Analysis
Animals were habituated to the testing environment daily for at least two days before baseline
testing. For testing mechanical sensitivity, animals were kept in boxes on an elevated metal
mesh floor and allowed 30 min for habituation before examination. The plantar surface of left
hindpaw was stimulated with a series of von Frey hairs with logarithmically incrementing
stiffness (0.02, 0.04, 0.08, 0.16, 0.32, 0.64, 1.28, and 2.56 g, Stoelting), presented perpendicular
to the plantar surface. The 50% paw withdrawal threshold was determined using Dixon’s up-
down method (Chaplan, et al., 1994). Heat sensitivity was assessed using radiant heat that was
applied to the plantar region of left hindpaw and the latency of its withdrawal response was
determined, using a plantar anesthesiometer (Ugo Basile, Italy). The intensity of radiant heat
was adjusted to elicit a response of around 10 s in normal mice. The cut off time was 20 seconds.
Drug Administration
To evaluate the systemic effect of morphine and D-JNKI-1 on tumor growth and tumor-induced
pain, vehicle (PBS), morphine (8 μmol mg/kg or 5 mg/kg), or D-JNKI-1 (2 μmol/kg or 6 mg/
kg), in a volume of 100 μl, was given intraperitoneally twice daily (7 AM and 7 PM) from day
5 to 9 after tumor inoculation. Nociceptive behaviors were evaluated before, 3 h and 12 h after
the first injection of that day. To evaluate spinal effect of D-JNKI-1 on tumor-induced pain,
vehicle or D-JNKI-1 (2 nmol) was delivered to cerebrospinal fluid via a lumbar puncture using
a 30G needle, and a volume of 10 μl liquid was given on day 13 after tumor inoculation, and
pain behaviors were examined 3 h after the spinal injection. D-JNK-I was kindly provided by
Dr. C. Bonny from University of Lausanne, Switzerland.
Immunohistochemistry
After appropriate survival times, the animals were deeply anesthetized with isoflurane and
perfused through the ascending aorta with saline followed by 4% paraformaldehyde with 1.5%
picric in 0.1 M PBS. After the perfusion, the L4-L5 spinal cord segments, L4, L5 dorsal root
ganglions (DRGs) and skin with tumor mass were removed and postfixed in the same fixative
overnight. Spinal cord sections (30 μm, free-floating sections), DRG sections (14 μm), and
skin sections (8 μm) were cut in a cryostat, and processed for immunofluorescence staining.
In brief, the sections were blocked with 2% goat serum, and incubated overnight at 4°C with
the following primary antibodies: GFAP antibody (mouse, 1:5000, Millipore), Iba-1 antibody
(rabbit, 1:5000, Wako), pJNK antibody (rabbit, 1:1000, Neuromics), p-c-Jun antibody (rabbit,
1:500, Cell Signaling), NeuN antibody (mouse, 1:5000, Millipore), prodynorphin antibody
(guinea pig, 1:1500, Neuromics), PKCγ antibody (rabbit, 1:1000, Santa Cruz), PGP-9.5
antibody (rabbit, 1:1000, Biogenesis), or ATF-3 antibody (rabbit, 1:500, Millipore). The
sections were then incubated for 1 h at room temperature with Cy3- or FITC-conjugated
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secondary antibodies (1:400, Jackson immunolab). The stained sections were examined with
a Nikon fluorescence microscope, and images were captured with a CCD Spot camera. The p-
c-Jun immunostaining was quantified by percentage of p-c-Jun positive neurons in the DRG
(Zhuang et al., 2006) and by the intensity of p-c-Jun immunofluorescence in the dorsal horn
from three animals per group.
Western Blots
To evaluate the JNK activation in tumor mass and spinal cord, tumor mass and spinal cord
were harvested on day 9 post-inoculation. The tissues were processed for Western blots. As
described previously (Zhuang, et al., 2006), animals were rapidly killed, and the L4-L5 spinal
segments were quickly removed and homogenized in a SDS sample buffer containing a mixture
of protease and phosphatase inhibitors (Sigma). Protein samples (30 μg) were separated on
SDS-PAGE gel and transferred to polyvinylidene difluoride blots. The blots were blocked with
5% milk and incubated overnight at 4°C with antibody against phosphorylated JNK (pJNK)
or GAPDH (loading control). These blots were further incubated with HRP-conjugated
secondary antibody, developed in ECL solution, and exposed onto Hyperfilm (Amersham
Biosciences, Arlington Heights, IL).
Bioluminescence Imaging and Tumor Growth Measurement
Mice were imaged at day 5 and 9 post inoculation by IVIS 100 Bioluminescence Imaging
System (Xenogen, Alameda, CA). Mice were anesthetized with a mixture of oxygen and 1.5%
of isoflurane and placed in prone position on the imaging platform, with the hindpaws taped
to the platform for better exposure of the tumor. Luciferase substrate D-Luciferin (Xenogen
Corp., Alameda, CA) in PBS was injected intraperitoneally (150 mg/kg) 5 minutes before
imaging. Images were acquired every five minutes for forty minutes with an exposure time
ranging from 5 to 10 seconds for every 5 minutes. Bioluminescence signals were quantified
using Living ImageR software by drawing regions of interest (ROI) over the tumor region to
obtain the normalized photons per second over the regions. The luminescence ratio of Day 5
and Day 9 post-inoculation (Day 9/Day 5) for treatment groups was used as an indicator of
tumor growth.
To assess the growth of melanoma in situ, the volume of left hindpaw was measured using the
plethysmometer (Ugo Basile, Italy). To further check the histology of tumor cells, hindpaw
skin with tumor mass were cut in a cryostat and sections were stained with hematoxylin and
eosin (HE).
In Vitro Cell Growth Assay
To determine the in vitro effect of D-JNKI-1 on tumor cell growth, we performed two cell
viability assays. B16-Fluc cells (10000, 5000, 2500 cells/well) plated in a 96-well flat bottom
plate were grown at 370C in 5% CO2/95% air for 24 h. Then the cells were treated with D-
JNKI-1 (0.1–50 μM) for 24 h. For the bioluminescence assay, cells were treated with D-
Luciferin (30 μg) at 37°C for 30 min, and the bioluminescence was measured by a Luminometry
(Victor 2 1420 Multilabel Counter Plate Reader, PerkinElmer Life Science). The MTT [3-(4,5-
dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay was processed according to
the manufacturer’s instructions (Millipore). The ratio of the absorbance of treated cells over
the control cells was calculated and used to represent the percentage of cell viability.
Statistical Analysis
Immunohistochemical and behavioral results were analyzed using t-test or one-way ANOVA
followed by Newman-Keuls multiple comparison test. Significance level was set at P < 0.05.
Data are presented as mean ± SEM.
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Results
Hindpaw melanoma inoculation produces profound tumor growth and cancer pain
After B16-Fluc melanoma cells were inoculated into the plantar region of a left hindpaw, there
was a progressive increase of paw volume, indicating the development of tumor mass (Fig.
1A). On post-inoculation day (PID) 15, the volume of the inoculated paw was increased to 197
± 5% (n = 9) of that of pre-inoculation (Fig. 1A).
Figure 1B shows a time course of consecutive bioluminescence images of a left hindpaw after
tumor inoculation. The luminescence intensity increased progressively from day 2 to day 16
post-inoculation, suggesting a continuous growth of tumor mass.
Tumor growth was also associated with a progressive development of pain hypersensitivity in
the hindpaw, which was characterized by mechanical allodynia (painful response to a normally
innocuous mechanical stimulus) and heat hyperalgesia (increased response to a noxious heat
stimulus) in the left hindpaws of inoculated mice. However, mice receiving vehicle (PBS)
injection did not show changes in paw volume and pain sensitivity (Fig. 1A, C and D). For
mechanical sensitivity, the paw withdrawal threshold (PWT) of the ipsilateral paw, in response
to von Frey hair stimulation, was decreased from 1.26 ± 0.04 g on day 0 before inoculation to
0.05 ± 0.003 g (n = 9) on PID-15 (Fig. 1C), indicating the development of mechanical allodynia.
For heat sensitivity, the paw withdrawal latency (PWL) of the inoculated hindpaw to heat
stimulation was decreased from 10.54 ± 0.28 s on day 0 to 3.5 ± 0.29 s (n = 9) on PID-15 (Fig.
1D), indicating the development of heat hyperalgesia. Both mechanical and heat pains
developed on PID-5 and reached a peak on PID-15 (Fig. 1C and 1D).
Despite massive tumor growth in hindpaws, the paw skin remained intact, and overall
conditions of mice were good in the first 2–3 weeks. After 3 weeks, we found melanoma
metastasis to the lung and animal conditions significantly deteriorated (data not shown). This
study focused on a period of the first 15 days, especially the first 9 days when animal conditions
are generally good but tumor growth and cancer pain are robust.
Hindpaw melanoma inoculation produces nerve degeneration
In support of increases in paw volume and luminescence intensity, HE staining demonstrated
a massive tumor cell infiltration in the dermis (Fig. 2A). To examine whether tumor growth
would cause nerve degeneration, we labeled nerve fibers in the hindpaw skin with PGP-9.5.
Tumor growth induced a robust reduction of PGP-9.5-labeled nerve fibers in the epidermis, as
well as in the dermis in the central skin area of tumor mass, on PID-9 (Fig. 2B), indicating a
nerve degeneration in this model.
To further determine whether tumor growth induces nerve injury, we examined the expression
of the transcription factor ATF-3, which is only expressed in DRG neurons with axonal injury
(Tsujino, et al., 2000). ATF-3 immunoreactivity was not found in the nucleus of vehicle treated
DRG neurons, but progressively increased in the ipsilateral L4/5 DRGs after tumor inoculation
(Fig. 2C). Around 20% of neurons in the L4 DRG expressed ATF-3 in the nuclei.
Hindpaw melanoma inoculation produces JNK activation in the DRG and spinal cord
To explore the role of JNK in cancer-associated pain, we examined JNK activation in the DRG
and spinal cord using a phosphorylated JNK (pJNK) antibody. As previously shown (Obata et
al., 2004; Zhuang et al., 2006), only very few neurons in the DRG exhibited weak pJNK
immunoreactivity in non-injured (vehicle-treated) conditions. However, after tumor
inoculation, many DRG neurons expressed pJNK (Fig. 2D).
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Western blotting showed that the mouse spinal cord mainly expressed pJNK1. In contrast,
pJNK2 level in the spinal cord was very low (Fig. 3A). Further, spinal pJNK1 levels were
significantly increased in tumor bearing mice on PID-9 (Fig. 3A).
Hindpaw melanoma inoculation produces glial activation and neurochemical changes in the
spinal cord
To further characterize this skin cancer pain model, we also examined glial activation and
neurochemical changes in the spinal cord that are associated with the development of chronic
pain. We have previously shown that spinal nerve ligation induces substantial glial activation
in the spinal cord such as up-regulation of GFAP, an astrocyte marker (Zhuang et al., 2006),
and Iba-1, a microglia marker (Jin et al., 2003). Intraplantar tumor inoculation also induced
marked upregulation of GFAP and Iba-1 in the spinal cord (Fig. 3B, C).
Further, nerve injury has been shown to produce neurochemical changes, such as up-regulation
of prodynorphin and PKCγ in dorsal horn neurons, and these changes are important for chronic
pain sensitization (Honore, et al., 2000; Malmberg, et al., 1997; Wang, et al., 2001). Similarly,
tumor inoculation induced a marked upregulation of prodynorphin (Fig. 4A) and PKCγ (Fig.
4B) in superficial dorsal horn neurons.
Semi-quantification of immunofluorescence indicated that all these glial and neural changes
in the spinal cord were significant in tumor-bearing mice (Table I).
Systemic and intrathecal inhibition of JNK with D-JNKI-1 attenuates cancer pain
We used two different protocols to test the effects of peptide inhibitor of JNK, D-JNKI-1, on
cancer-induced pain. In the first protocol, we gave repeated intraperitoneal injections of D-
JNKI-1, twice a day, 12 h apart, for 5 days, starting from PID-5, when cancer pain began to
develop. We tested cancer pain at 3 h and 12 h after the first daily injection on that day. D-
JNKI-1 markedly inhibited mechanical allodynia at 3 h (Fig. 5A). Interestingly, the anti-
allodynic effect of D-JNKI-1 was progressively increased after repeated injections, from PID-5
to PID-9 (Fig. 5A), suggesting an accumulative effect of the drug.
To confirm that these behavioral effects of D-JNKI-1 result from specific inhibition of the JNK
pathway, we examined the phosphorylation of the transcription factor c-Jun, a critical
downstream target of JNK. In normal conditions, only few neurons in the DRG expressed p-
c-Jun (Zhuang et al., 2006). However, after tumor implantation, 47.5 ± 0.6% DRG neurons
expressed p-c-Jun. Importantly, this tumor-induced increase in p-c-Jun levels was suppressed
by DJNKI-1 (daily injections from day 5 to day 9). Thus, only 23.4 ± 0.5% DRG neurons
expressed p-c-Jun after the treatment (P<0.01, n=3). Further, p-c-Jun levels in the spinal cord
dorsal horn in tumor-bearing mice were reduced by D-JNKI-1; and the intensity of p-c-Jun
staining in tumor-bearing mice decreased from 43.5±1.0 (vehicle-treated) to 38.4±1.1 (D-
JNKI-1-treated, P<0.01, n=3).
As a comparison, we also tested the effects of morphine, a commonly used analgesic for patients
with terminal cancer. Like JNK, morphine was injected twice a day for 5 days, at the dose of
8 μmol/kg (5 mg/kg, i.p.). This does is 4 times higher than that of D-JNKI-1 at mole scale.
After the first injection, morphine significantly attenuated tumor-induced mechanical allodynia
at 3 h (Fig. 5A). However, repeated injections of morphine produced a very rapid analgesic
tolerance, a reduction in analgesic efficacy, which appeared on the second day. Morphine
completely lost its anti-allodynic effect after 3 days (Fig. 5A).
Initial injection of D-JNKI-1 on day 5 did not attenuate tumor-induced heat hyperalgesia.
However, repeated injections of D-JNKI-1 attenuated tumor-induced heat hyperalgesia on
PID-8 and PID-9 (Fig. 5B), again supporting an accumulating effect of D-JNKI-1 on heat
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hyperalgesia. However, repeated morphine injections did not inhibit heat hyperalgesia from
day 5 to 9, when tested 3 h after injections (Fig. 5B). To investigate long lasting and
accumulating effects of D-JNKI-1, we also tested tumor-induced mechanical allodynia at 12
h after the first daily drug injection. Repeated injections of D-JNKI-1 (6 mg/kg) but not
morphine (5 mg/kg) also attenuated tumor-induced mechanical allodynia from day PID-7 to
PID-9 in an accumulative manner (Fig. 5C).
To further determine the role of spinal cord JNK in cancer pain, we performed a single bolus
injection of D-JNKI-1 (2 nmol) via an intrathecal route on PID-13. A single spinal injection
of D-JNKI-1 suppressed tumor-induced mechanical allodynia but not heat hyperalgesia at 3 h
(Fig. 6).
We also examined the effects of D-JNKI-1 on melanoma-induced glial activation and
neurochemical changes in the spinal cord on PID-9 after repeated intraperitoneal injections.
Interestingly, D-JNKI-1 had different effects on these changes. While melanoma-induced up-
regulation of prodynorphin was almost completely blocked by D-JNKI-1, melanoma-induced
up-regulation of Iba-1, GFAP, and PKCγ was not significantly reduced by the JNK inhibitor
(Table I).
D-JNKI-1 suppresses tumor growth both in vivo and in vitro
To determine whether JNK inhibition would affect tumor growth in vivo, we measured hindpaw
volume from PID-5 to PID-9. Tumor growth (i.e., increase in the volume of the inoculated
hindpaw) was significantly inhibited by D-JNKI-1, but not by morphine, on PID 7–9, as
compared with vehicle control group (Fig. 7A). We also measured tumor growth by
luminescence ratio (Day 9/Day 5). In vehicle-treated animals, the ratio increased to 1.99 ± 0.27
(n = 11). But in D-JNKI-1-treated animals, the ratio remained unchanged (1.01 ± 0.22, n = 10),
indicating an inhibition of tumor growth after D-JNKI-1 treatment (Fig. 7B). In contrast,
morphine had no effect on tumor growth when measured by luminescence ratio (Fig. 7B).
Finally, we examined the effects of the JNK inhibitor in cultured B16-Fluc melanoma cells.
Both the bioluminescence and MTT viability assay revealed that D-JNKI-1, at the
concentrations of 0.1–50 μM, dose-dependently inhibited tumor cell proliferation and viability
(Fig. 7C and 7D).
Discussion
The melanoma model of cancer pain
Animal models of cancer pain have been developed to test mechanisms and treatments of this
pain (Mantyh, 2006). Intramedullary inoculation of tumor cells was used to induce bone cancer
pain (Schwei, et al., 1999), which is the most frequently encountered type of cancer pain in
patients (Mercadante, 1997). In this model, the neurochemical changes are different from that
in inflammatory and neuropathic pain models (Honore, et al., 2000). For example, in the
primary afferents, there is no up-regulation of the neuropeptide substance P, which is seen in
inflammatory pain conditions, or down-regulation of substance P, which is seen in neuropathic
pain conditions (Honore, et al., 2000). However, up-regulation of prodynorphin and activation
of astrocytes (GFAP up-regulation) were found in all three pain conditions (Honore, et al.,
2000; Ji, et al., 2002; Wang, et al., 2001; Zhuang, et al., 2006). Microglia activation in the
spinal cord was also found in a bone cancer pain model (Zhang, et al., 2005).
Intraplantar inoculation of lung carcinoma cells (Constantin, et al., 2008) or melanoma cells
(Sasamura, et al., 2002) into hindpaws of mice was used to induce skin cancer pain, because
cancer pain and tumor growth can be easily measured in the hindpaws. Inoculation of
luciferase-transfected bioluminescent melanoma cells into a hindapw has provided a model for
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real-time longitudinal analyses of tumor growth in live mice (Craft, et al., 2005). Importantly,
aggressive skin cancer or metastatic melanoma is associated with pain (Leach, et al., 2008;
Lehembre, et al., 2006). We showed that intraplantar inoculation of melanoma cells induced
robust pain hypersensitivity including mechanical allodynia and heat hyperalgesia. In
particular, this model showed marked peripheral neuropathy, as indicated by a loss of PGP-9.5-
lableld nerve fibers in the hindpaw skin, up-regulation of ATF-3 in DRG neurons, and profound
activation of microglia and astrocytes in the spinal cord. Thus, our skin cancer pain model may
share mechanisms with peripheral neuropathic pain. Nerve degeneration in the skin was also
found after implantation of fibrosarcoma cells in and around the calcaneus bone (Cain, et al.,
2001), but not evident in another skin cancer pain model induced by intraplantar inoculation
of lung carcinoma cells (Constantin, et al., 2008). Interestingly, in another melanoma model,
PGP-9.5-labeled nerve fibers disappear in the center of tumor mass but increase in the periphery
of the tumor (Zhang, et al., 2003). Thus, different skin cancer pain models may have different
features, depending on types of tumor cells, stages of tumor growth, and interaction between
tumor cells and surrounding tissues and nerves.
JNK and cancer pain
We previously showed that spinal nerve ligation induced JNK activation in the spinal cord,
and spinal injection of the peptide inhibitor D-JNKI-1 and small molecule inhibitor SP600125
could attenuate nerve ligation-induced mechanical allodynia (Zhuang, et al., 2006). pJNK1
appears to be the predominant JNK isoform activated in the spinal cord of both rat and mouse.
JNK1 is known to express in spinal cord astrocytes (Obata, et al., 2004; Zhuang, et al., 2006).
pJNK1 also increased in the spinal cord after melanoma inoculation and spinal injection of D-
JNKI-1 attenuated melanoma-induced mechanical allodynia. We further demonstrated that
systemic injections of D-JNKI-1 persistently inhibited melanoma-induced mechanical
allodynia. Because D-JNKI-1 with TAT sequence is cell-permeable, it can be taken up by cells
in the central nervous system after systemic injection (Borsello and Bonny, 2004).
Interestingly, repeated injections of D-JNKI-1 showed an accumulative anti-allodynic effect
without producing tolerance. For example, three days after repeated injections, D-JNKI-1 not
only inhibited allodynia at 3 h but also at 12 h after the previous injection (Fig. 4C).
Furthermore, melanoma-induced heat hyperalgesia was not inhibited by single injection of D-
JNKI-1 via spinal and systemic route, but inhibited 3 days after repeated injections of D-JNKI-1
(Figs. 4, 5).
We observed marked up-regulation of Iba-1 (microglia marker) and GFAP (astrocyte marker)
in the spinal cord after melanoma inoculation. But these glial changes were not significantly
inhibited by D-JNKI-1, in agreement with our previous study (Zhuang, et al., 2006). Thus, the
anti-allodynic effect of D-JNKI-1 is not associated with reversal of these spinal glial changes.
However, D-JNKI-1 suppressed melanoma-induced up-regulation of prodynorphin in dorsal
horn neurons. Prodynorphin is essential for the development of neuropathic pain development
(Wang, et al., 2001). Our recent study also shows that spinal JNK activation produces the
chemokine CCL2 for neuropathic pain sensitization (Gao et al., 2009). JNK may also increase
cancer pain via peripheral mechanism, since tumor inoculation and nerve injury also activate
JNK in DRG neurons (Fig. 2D, Obata, et al., 2004; Zhuang, et al., 2006) and the spinal nerve.
Further, inhibition of tumor growth by D-JNKI-1 (see below) could indirectly alleviate cancer
pain.
JNK and tumor growth
The American Cancer Society has estimated that approximately 9,000 people die each year
from skin cancer and about 7,000 of these deaths are from melanoma. Activation of JNK is
associated with cell proliferation and shorter relapse-free period for patients with superficial
spreading melanomas, serving as a potential marker for malignant melanoma (Jorgensen, et
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al., 2006). JNK inhibition was found to induce cell cycle arrest and apoptosis in human
melanoma cells (Alexaki, et al., 2008). The major effector of JNK, c-Jun, is a potential target
for anticancer cell therapy (Gurzov, et al., 2008). JNK inhibitor SP600125 inhibits tumor
growth and interferes with tumor angiogenesis, a critical process for tumor growth (Ennis, et
al., 2005). In gastrointestinal cancer cells, SP600125 inhibits cell proliferation and induces
apoptosis and cell cycle arrest (Xia, et al., 2006). We have shown that repeated injections of
D-JNKI-1 inhibited melanoma growth in the hindpaw as measured both by paw volume and
luminescence intensity. Further, D-JNKI-1 inhibited proliferation of melanoma in cultured
melanoma cells, indicating a direct effect of D-JNKI-1 on melanoma cells. JNK activation is
also important for the expression of vascular endothelial growth factor (VEGF) in malignant
cells (Krejsgaard, et al., 2006; Yoshino, et al., 2006), an essential molecule for angiogenesis
(Einspahr, et al., 2007). The tumor suppressing effect of D-JNKI-1 may also be associated with
its inhibition on angiogenesis.
Morphine and cancer pain
Morphine is the major drug of choice in the terminal stage of cancer pain. Humans suffering
from bone cancer pain generally require significantly higher doses of morphine as compared
to individuals with inflammatory pain. The doses of morphine required to block bone cancer
pain in mouse are ten times that required to block peak inflammatory pain behaviors (Luger,
et al., 2002; Menendez, et al., 2003; Wacnik, et al., 2001). Sasamura et al. reported that
subcutaneous morphine, at the dose of 5 mg/kg, inhibits melanoma-induced heat hyperalgesia
(Sasamura, et al., 2002). In our study, this dose of morphine inhibited melanoma-induced
mechanical allodynia but not heat hyperalgesia when tested after 3 hours. Repeated injections
of morphine (5 mg/kg, twice a day) induced a rapid development of analgesic tolerance in the
second day, which is faster than that seen in another skin cancer model (Andoh, et al., 2008).
Morphine-induced tolerance leads to increased drug consumption and incidence of unwanted
side effects, such as sedation, constipation, itching, nausea, vomiting and respiratory
depression (Mao, 2002; McNicol, et al., 2003). Morphine also induces rapid tolerance in
neuropathic pain models (Bulka, et al., 2002; Raghavendra, et al., 2002; Tawfik, et al., 2005).
The rapid development of morphine tolerance in melanoma bearing mice further supports a
neuropathic involvement in this cancer pain model. Our data suggest that morphine only has
limited role in controlling the pain symptoms in aggressive skin cancer states.
Morphine was shown to suppress tumor growth in a melanoma model. This anti-tumor effect
of morphine may be associated with the analgesic effect of morphine, because cancer pain
results in psychological stress that will suppress immune functions and enhance tumor growth
(Sasamura, et al., 2002). In contrast, morphine at high doses enhances tumor growth due to the
suppression of immune system (Lewis, et al., 1983). In this study, morphine had no effect on
the growth of melanoma, which is correlated with limited analgesic effect of morphine in the
melanoma model.
Concluding remarks
We have characterized a skin cancer pain model induced by intraplantar inoculation of
melanoma cells into a hindpaw. This model is characterized by robust tumor growth and rapid
development of mechanical and heat hypersensitivity and exhibits marked peripheral
neuropathy. Given the low incidence of pain in melanoma patients, this model may not be very
clinically relevant compared to other models, such as bone cancer pain models. However, this
model is very convenient to study mechanisms of cancer pain and tumor growth and to test
new treatment. Future studies will be needed to test the role of the JNK pathway in other cancer
pain models. Our data have shown that repeated administration of the peptide inhibitor of JNK,
D-JNKI-1, not only attenuates melanoma-induced mechanical allodynia but also suppresses
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tumor growth both in vivo and in vitro. In contrast, repeated administration of morphine
produces rapid analgesic tolerance and shows no effect on tumor growth.
It is worthwhile to compare JNK with its family member p38. Both MAPKs are pronociceptive
(Obata and Noguchi, 2004; Ji, et al., 2007). Spinal administration of p38 inhibitors was shown
to attenuate inflammatory pain and neuropathic pain in different models (Jin, et al., 2003;
Schafers, et al., 2003; Svensson, et al., 2003; Obata et al., 2004). However, oral delivery of the
p38 inhibitor SCIO-469 shows no effect on osteosarcoma-induced cancer pain (Svensson, et
al., 2008). In contrast to D-JNKI-1, SCIO-469 has poor CNS penetration after systemic
administration. It is also possible that p38 plays limited role in cancer pain. Our data have
shown that inhibition of the JNK pathway can directly suppress the proliferation of melanoma
cells. Notably, most deaths from skin cancer result from melanoma (Jemal, et al., 2001) and
aggressive skin cancer is associated with pain (Leach, et al., 2008; Lehembre, et al., 2006).
Therefore, inhibition of the JNK pathway with one stone can hit two birds: cancer pain and
tumor growth. Finally, a recent clinical study suggests that the peptide inhibitor D-JNKI-1 can
be well tolerated by patients and shows efficacy in treating acute acoustic trauma (Suckfuell,
et al., 2007). Thus, D-JNKI-1 may be a promising therapeutic agent for the treatment of
melanoma and cancer-related pain.
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Figure 1.
Time course of tumor growth and cancer pain development following intraplantar injection of
luciferase-transfected B16-Fluc melanoma cells. (A) Increase of paw volume after inoculation.
Inset shows the tumor-bearing hindpaw (left) 15 days after inoculation. (B) Bioluminescent
imaging shows enhanced luminescence intensity over time in an inoculated hindpaw,
indicating a continuous growth of melanoma. (C, D) Development of mechanical allodynia
(C) and heat hyperalgesia (D) in the inoculated paws. *P < 0.05 vs. vehicle (PBS) control.
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Figure 2.
Nerve degeneration in the tumor bearing hindpaws. (A) Hematoxylin-eosin (HE) staining of
hindpaw skin (plantar surface) 9 days after tumor inoculation. The tumor tissue (indicated with
*) was located in the dermis. Scale bar, 400 μm. (B) PGP-9.5 immunostaining of hindpaw skin
(plantar surface) reveals a loss of nerve fibers 9 days after tumor inoculation. Arrows indicated
nerve fibers in the epidermis. (C) ATF-3 immunostaining indicates induction of ATF-3 in the
nuclei of many DRG neurons after tumor inoculation. Scale bar, 100 μm. (D) pJNK
immunostaining shows JNK activation in DRG neurons after tumor inoculation. Scale bar, 50
μm.
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Figure 3.
Activation of JNK, microglia, and astrocytes in the spinal cord after tumor inoculation. (A)
Western blot shows increased pJNK1 but not pJNK2 levels in the spinal cord 9 days after
inoculation. pJNK level in the spinal cord was quantified by the density of specific Western
bands that are normalized by GAPDH loading control. *, P<0.05, n=3. (B, C)
Immunohistochemistry shows microglia activation (up-regulation of Iba-1, B) and astrocyte
activation (up-regulation of GFAP, C) in the ipsilateral spinal cord 9 days after tumor
inoculation. Right panels: high power views of the ipsilateral dorsal horn insets in the laminae
I-II. Scale bar, 200 μm (left panels), 100 μm (right panels).
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Figure 4.
Immunohistochemistry shows up-regulation of prodynorphin (B) and PKCγ in the ipsilateral
superficial dorsal horn 9 days after tumor inoculation. Scale bar, 100 μm.
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Figure 5.
Inhibition of melanoma-induced cancer pain by systemic injection of the JNK inhibitor D-
JNKI-1. (A, B) Repeated injections of D-JNKI-1 (2 μmol or 6 mg/kg, i.p., twice a day) inhibit
melanoma-induced mechanical allodynia as measured by paw withdrawal threshold (A) and
heat hyperalgesia as measured by paw withdrawal latency (B). As comparison, repeated
injections of morphine (8 μmol or 5 mg/kg, i.p., twice a day) only produce mild inhibition of
mechanical allodynia with rapid development of tolerance. Pain behavior was tested 3 hours
after the previous injection. (C) Repeated injections of D-JNKI-1 (6 mg/kg, i.p., twice a day)
but not morphine (5 mg/kg, i.p., twice a day) also inhibit melanoma-induced mechanical
allodynia when tested 12 hours after the previous injection. *P<0.05 vs. vehicle (PBS) control.
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Drugs were injected intraperitoneally twice daily from day 5 to 9 after tumor inoculation. Note
accumulating effects of D-JNKI-1 on cancer pain after repeated injections.
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Figure 6.
Inhibition of melanoma-induced mechanical allodynia (A) but not heat hyperalgesia (B) after
spinal injection of D-JNKI-1 (2 nmol). The drug was injected on day 13 after tumor inoculation
and pain behavior was tested 3 hours after the drug injection. *P < 0.05 vs. vehicle control
(normal saline).
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Figure 7.
Inhibition of melanoma tumor growth by D-JNKI-1 both in vivo and in vitro. (A) Repeated
injections of D-JNKI-1 (6 mg/kg, i.p., twice a day) but not morphine (5 mg/kg, i.p., twice a
day) inhibit melanoma growth as measured by paw volume. Drugs were injected
intraperitoneally twice daily from day 5 to 9 after tumor inoculation. *P < 0.05 vs. vehicle
control group. Inset shows increases in pJNK1 and pJNK2 levels in hindpaw tumor mass 9
days after inoculation of melanoma cells. (B) Luminescence ratio (Day 9/Day 5) also shows
suppression of tumor growth in D-JNKI-1-treated mice. *P < 0.05 vs. vehicle control group.
(C, D) In vitro bioluminescence assay (C) and MTT viability assay (D) reveal that D-JNKI-1
dose-dependently inhibit melanoma cell proliferation (C) and viability (D). *P < 0.05 vs.
vehicle control group. Each condition was repeated in 3–5 different cultures.
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Table I
Quantitative analysis of neurochemical changes and glial changes in the spinal cord of melanoma bearing mice and
the effects of the JNK inhibitor D-JNKI-1. GFAP and Iba-1 levels in the dorsal horn were quantified by the density of
immunostaining. Prodynorphin and PKCγ levels in the superficial dorsal horn were quantified by counting the number
of positive neurons. The data of GFAP and Iba-1 are presented as percent of vehicle (PBS) control. D-JNKI-1 (6 mg/
kg) was injected intraperitoneally twice a day from day 5 to 9 after tumor inoculation.
Vehicle Tumor + Vehicle Tumor + D-JNKI-1
GFAP 100 ± 13.2 231.8 ± 15.2* 220.2 ± 22.6
Iba-1 100 ± 8.7 247.2 ± 24.4 * 196.2 ± 13.3
Prodynorphin 7.0 ± 0.6 11.4 ± 0.6* 7.7± 0.4 #
PKCγ 34.1 ± 2.9 50.3 ± 2.3* 50.1 ± 5.4
*
P< 0.05, compared with vehicle control;
#
P<0.05, compared with tumor; n=3–5.
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